Statement of Changes in Beneficial Ownership (4)
March 03 2020 - 12:40PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Sprague John M |
2. Issuer Name and Ticker or Trading Symbol
T2 Biosystems, Inc.
[
TTOO
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Financial Officer |
(Last)
(First)
(Middle)
101 HARTWELL AVENUE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/21/2020 |
(Street)
LEXINGTON, MA 02421
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 2/21/2020 | | M | | 10000 | A | (1) | 26388 (2) | D | |
Common Stock | 2/24/2020 | | S | | 4166 | D | $0.82 (3) | 22222 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Restricted Stock Units | (1) | 2/21/2020 | | M | | 10000 | | (4) | (4) | Common Stock | 10000 | $0.00 | 20000 | D | |
Explanation of Responses: |
(1) | Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
(2) | Includes 876 shares acquired under the Issuer's employee stock purchase plan ("ESPP") on November 15, 2018, 1,508 shares acquired under the ESPP on May 15, 2019 and 2,331 shares acquired under the
ESPP on November 15, 2019. |
(3) | The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $0.80 to $0.87. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
(4) | On February 21, 2019 the reporting person was granted 30,000 RSU's that vest in three equal annual installments beginning on February 21, 2020. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Sprague John M 101 HARTWELL AVENUE LEXINGTON, MA 02421 |
|
| Chief Financial Officer |
|
Signatures
|
/s/ Michael Gibbs, Attorney-in-fact | | 3/3/2020 |
**Signature of Reporting Person | Date |
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Aug 2024 to Sep 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Sep 2023 to Sep 2024